Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.
Diego Villa, MD, FRCPC
Advertisement
Articles by Diego Villa, MD, FRCPC
Advertisement
Latest Updated Articles
Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCLPublished: January 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Steven W. Pipe, MD, on Integrating Gene Therapy into Clinical Care for Hemophilia B
2
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL
3
Brian Lin, PhD, on Using Genetics, Biomarkers, and Clinical Trial Readiness to Enhance ALS Care
4
Data Roundup: December 2025 Features Updates from ASH and CTAD
5